Go Pro
→ 'How Much Can I Actually Spend Each Year With $2.5M Saved?' (From SmartAsset) (Ad)tc pixel Free SCLXW Stock Alerts

Scilex (SCLXW) Competitors

Scilex logo
$0.09 0.00 (-0.11%)
As of 09/29/2026 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SCLXW vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Scilex stock or one of its competitors? Scilex's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scilex compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Scilex (NASDAQ:SCLXW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Scilex N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Scilex$31.61MN/AN/AN/AN/A

In the previous week, Scilex had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Scilex and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.82 beat Scilex's score of 0.89 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Scilex Positive

Summary

Scilex beats 60 Degrees Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Biofrontera?

Scilex (NASDAQ:SCLXW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$31.61MN/AN/AN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

In the previous week, Scilex had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Scilex and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.79 beat Scilex's score of 0.89 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Scilex Positive
Biofrontera Very Positive

Company Net Margins Return on Equity Return on Assets
ScilexN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Biofrontera beats Scilex on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Scilex (NASDAQ:SCLXW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Scilex N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Scilex$31.61MN/AN/AN/AN/A

In the previous week, Scilex had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Scilex and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.82 beat Scilex's score of 0.89 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Very Positive
Scilex Positive

Summary

Scilex beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Clever Leaves?

Scilex (NASDAQ:SCLXW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Scilex has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$31.61MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

Company Net Margins Return on Equity Return on Assets
ScilexN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Scilex had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for Scilex and 0 mentions for Clever Leaves. Scilex's average media sentiment score of 0.89 beat Clever Leaves' score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company Overall Sentiment
Scilex Positive
Clever Leaves Neutral

Summary

Scilex beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

How does Scilex compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Scilex (NASDAQ:SCLXW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Scilex had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for Scilex and 0 mentions for Comera Life Sciences. Scilex's average media sentiment score of 0.89 beat Comera Life Sciences' score of 0.00 indicating that Scilex is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Scilex Positive

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Scilex N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Scilex$31.61MN/AN/AN/AN/A

Summary

Scilex beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLXW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLXW vs. The Competition

Export
MetricScilexPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.69B$7.34B$13.04B
Dividend YieldN/A2.62%2.52%14.18%
P/E RatioN/A787.37273.7825.68
Price / SalesN/A833.31616.1475.92
Price / CashN/A91.3280.0652.35
Price / BookN/A10.6110.416.34
Net IncomeN/A$2.83B$3.50B$360.56M
7 Day PerformanceN/A-1.13%-1.41%-1.60%
1 Month PerformanceN/A-1.37%-4.16%-4.10%
1 Year PerformanceN/A0.33%12.62%3.79%

Scilex Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLXW
Scilex
N/A$0.09
-0.1%		N/A-60.9%$0.00$31.61MN/A34
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
-22.9%		N/A-18.7%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
-2.9%		N/A-85.6%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
+6.0%		N/A-88.7%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-75.0%$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCLXW) was last updated on 9/30/2026 by MarketBeat.com Staff.
From Our Partners
This Nasdaq Name Spent 25 Years Preparing for America's Next Big Move
A Nasdaq listed company has spent more than 25 years developing professional drone technology now central to W...
i2i Marketing Group, LLC | Sponsoredtc pixel
Dr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”
Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...
Altimetry | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...
Stansberry Research | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel